The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

Life-threatening lung cancer has taught me many valuable lessons and made my new normal so fulfilling. My life has changed ...

The exact survival rate for BRAF-positive NSCLC is not well documented. According to the American Cancer Center, the 5-year survival rate of NSCLC (all types) is: localized (tumor has not spread ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

A recent study reveals that continuing immunotherapy beyond disease progression significantly improves survival rates in patients with advanced non-small cell and small cell lung cancers, particularly ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell ...

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...

The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...